drugset / Trial / NCT00154882
Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary endpoint of this phase II trial is the objective response rate of the stage I (low-dose) regimen. The secondary endpoints include treatment-related toxicity, the change in quality of life, progression free survival and overall survival.
Timeline
- Start
- 2003-09
- Primary completion
- —
- Completion
- 2007-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Paclitaxel | Small molecule | 40 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 50 mg/m2 | — |